pharma · Severe Alpha-1 Antitrypsin Deficiency (AATD)
Grifols
Instituto Grifols S.A.
Instituto Grifols is a pharma organization headquartered in EU. Primary therapeutic focus areas include Severe Alpha-1 Antitrypsin Deficiency (AATD). NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 p
ES HQ
1909 Founded
14,121 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- ES
- Founded
- 1909
- Employees
- 14,121
- Programs
- 2
- Drugs
- 2
- Patents
- 0
PPRO24-001
Phase 3 · small molecule · Severe Alpha-1 Antitrypsin Deficiency (AATD)
PPRO24-001 for Severe Alpha-1 Antitrypsin Deficiency (AATD) is a Phase 3 program (small_molecule) at Instituto Grifols S.A. with 1 ClinicalTrials.gov record(s).
Internal code PPRO24-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Instituto Grifols S.A.
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Severe Alpha-1 Antitrypsin Deficiency (AATD)
- Status
- active
- Trials
- 1